Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew J Ellis

Showing results (191-200 of 285) with videos related to

Pageof 29
Sort By:
JCI Insight|July 24, 2020
Pharmacogenomics of aromatase inhibitors in postmenopausal breast cancer and additional mechanisms of anastrozole actionJunmei Cairns, James N Ingle, Tanda M Dudenkov, et al.
Cancer Discovery|August 13, 2017
Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast CancerSvasti Haricharan, Nindo Punturi, Purba Singh, et al.
Cancer Research|May 31, 2018
FGFR1-Activated Translation of WNT Pathway Components with Structured 5' UTRs Is Vulnerable to Inhibition of EIF4A-Dependent Translation InitiationTuan M Nguyen, Elena B Kabotyanski, Yongchao Dou, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|November 19, 2020
Transplant social worker and donor financial assistance to increase living donor kidney transplants among African Americans: The TALKS Study, a randomized comparative effectiveness trialL Ebony Boulware, Debra L Sudan, Tara S Strigo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 26, 2009
A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumorsKwok-K Wong, Paula M Fracasso, Ronald M Bukowski, et al.
Pharmacogenetics and Genomics|July 11, 2020
Single-nucleotide polymorphism biomarkers of adjuvant anastrozole-induced estrogen suppression in early breast cancerJames N Ingle, Krishna R Kalari, Poulami Barman, et al.
Cancer Research|February 18, 2017
Targeted Degradation of BET Proteins in Triple-Negative Breast CancerLongchuan Bai, Bing Zhou, Chao-Yie Yang, et al.
Nature Genetics|October 24, 2018
Long noncoding RNA MALAT1 suppresses breast cancer metastasisJongchan Kim, Hai-Long Piao, Beom-Jun Kim, et al.
NPJ Breast Cancer|April 14, 2022
LINC00355 regulates p27<sup>KIP</sup> expression by binding to MENIN to induce proliferation in late-stage relapse breast cancerAbdallah M Eteleeb, Prasanth K Thunuguntla, Kyla Z Gelev, et al.
British Journal of Cancer|September 1, 2025
Correction: RON signalling promotes therapeutic resistance in ESR1 mutant breast cancerDerek Dustin, Guowei Gu, Amanda R Beyer, et al.
Pageof 29

Showing results (191-200 of 285) with videos related to

Sort By:
Pageof 29
JCI Insight|July 24, 2020
Pharmacogenomics of aromatase inhibitors in postmenopausal breast cancer and additional mechanisms of anastrozole actionJunmei Cairns, James N Ingle, Tanda M Dudenkov, et al.
Cancer Discovery|August 13, 2017
Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast CancerSvasti Haricharan, Nindo Punturi, Purba Singh, et al.
Cancer Research|May 31, 2018
FGFR1-Activated Translation of WNT Pathway Components with Structured 5' UTRs Is Vulnerable to Inhibition of EIF4A-Dependent Translation InitiationTuan M Nguyen, Elena B Kabotyanski, Yongchao Dou, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|November 19, 2020
Transplant social worker and donor financial assistance to increase living donor kidney transplants among African Americans: The TALKS Study, a randomized comparative effectiveness trialL Ebony Boulware, Debra L Sudan, Tara S Strigo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 26, 2009
A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumorsKwok-K Wong, Paula M Fracasso, Ronald M Bukowski, et al.
Pharmacogenetics and Genomics|July 11, 2020
Single-nucleotide polymorphism biomarkers of adjuvant anastrozole-induced estrogen suppression in early breast cancerJames N Ingle, Krishna R Kalari, Poulami Barman, et al.
Cancer Research|February 18, 2017
Targeted Degradation of BET Proteins in Triple-Negative Breast CancerLongchuan Bai, Bing Zhou, Chao-Yie Yang, et al.
Nature Genetics|October 24, 2018
Long noncoding RNA MALAT1 suppresses breast cancer metastasisJongchan Kim, Hai-Long Piao, Beom-Jun Kim, et al.
NPJ Breast Cancer|April 14, 2022
LINC00355 regulates p27<sup>KIP</sup> expression by binding to MENIN to induce proliferation in late-stage relapse breast cancerAbdallah M Eteleeb, Prasanth K Thunuguntla, Kyla Z Gelev, et al.
British Journal of Cancer|September 1, 2025
Correction: RON signalling promotes therapeutic resistance in ESR1 mutant breast cancerDerek Dustin, Guowei Gu, Amanda R Beyer, et al.
Pageof 29